Sunil Sharma
Professor
Department of Internal Medicine
Huntsman Cancer Institute
United States of America
Biography
Sunil Sharma, MD, is the Deputy Director of Huntsman Cancer Institute, the Director of the Center for Investigational Therapeutics (CIT), and an investigator at Huntsman Cancer Institute (HCI). Sharma is also a professor in the School of Medicine at the University of Utah and the Co-Leader of the Experimental Therapeutics Program at HCI. He holds a Jon and Karen Huntsman Presidential Professorship in Cancer Research. Sharma is an expert in the development and testing of new cancer therapies. At HCI, he is working to increase the portfolio of high-quality clinical trials, including phase I trials. He is also establishing a translational oncology lab to support related studies. In addition, his clinical interests are focused on treatment of patients with gastrointestinal cancers (colon, pancreatic, esophageal, rectal, liver), mesothelioma, and rare tumors (carcinoid, neuroendocrine tumors, and carcinomas of unknown primarys). Before joining HCI, Sharma built a phase I clinical trials program at the Nevada Cancer Institute where he oversaw more than 25 clinical trials. He led a global oncology drug development program at the drug manufacturing company Novartis. He also worked as a physician in the Division of Gastrointestinal Oncology at Memorial Sloan-Kettering Cancer Center, New York City. He earned a medical degree at the University of Delhi, New Delhi, India.
Research Interest
Clinical Trials, Phase I Gastrointestinal Cancers Targeted Drug Delivery Systems Small Molecule Targeted Drug Discovery
Publications
-
Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA (2014). Colon cancer, version 3.2014. J Natl Compr Canc Netw, 12(7), 1028-59.
-
Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN (2015). Pre-clinical efficacy of combined therapy with novel beta-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia, 29(6), 1267-78.
-
Sharma S, Witteveen PO, Lolkema MP, Hess D, Gelderblom H, Hussain SA, Porro MG, Waldron E, Valera SZ, Mu S (2015). A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemother Pharmacol, 75(1), 87-95.
